IDEX Corporation (IEX) has been benefiting from strong momentum in the Fire & Safety/Diversified Products (FSDP) segment and accretive acquisitions despite weakness in the Health & Science Technologies (HST) unit, the rising cost of sales and forex woes. Let us discuss the factors why investors should retain the stock for the time being. Growth Catalysts Business Strength: IDEX is benefiting from the strong performance of the FSDP segment, driven by increasing orders from industrial and municipal markets. T ...

IDEX Biometrics ASA held its annual general meeting on 16 May 2024. 95.3 million shares or 34% of the capital was represented at the meeting. All resolutions were passed as proposed by the board and nomination committee. Marianne Bøe, Head of investor relations E-mail: marianne.boe@idexbiometrics.com Tel: + 47 9180 0186 About IDEX Biometrics IDEX Biometrics ASA (OSE: IDEX) is a global technology leader in fingerprint biometrics, offering authentication solutions across payments, access control, and digital ...

Aligned with the restructuring of IDEX's organization to consolidate development and business operations to be located primarily in the UK and the EU/EEA, and to reduce costs, the nomination committee proposes that IDEX also reduces the size of the board of directors to a total of three. For further information contact: Marianne Bøe, Head of Investor Relations E-mail: marianne.boe@idexbiometrics.com Tel: + 47 918 00186 About IDEX Biometrics IDEX Biometrics ASA (OSE: IDEX) is a global technology leader in fi ...

Oslo, Norway – 16 May 2024 - IDEX Biometrics will give a webcast presentation today at 09:00 CET in connection with its interim report for the first quarter of 2024. The presentation will be held by Vince Graziani, Chief Executive Officer, and Catharina Ekløf, Chief Commercial and Operating Officer. The webcast presentation can be viewed at the following link: https://idexbiometrics.videosync.fi/q1-2024 The presentation file is also available on the IDEX Biometrics website: www.idexbiometrics.com/investors ...

Oslo, Norway – 16 May 2024 - IDEX Biometrics ASA's interim report for the first quarter of 2024 is attached to this notice (link below) The interim report is also available on the IDEX Biometrics website: www.idexbiometrics.com/investors/interim-results/ A webcast presentation of the interim report will be held by Vince Graziani, Chief Executive Officer, today at 09:00 CET. The webcast presentation slide deck is attached to this notice (link below). Last year we focused on laying the foundation for biometri ...

Oslo, 15 May 2024 Reference is made to the stock exchange notice from IDEX Biometrics ASA ("IDEX" or the "Company") on 15 May 2024 regarding a private placement of shares in the Company raising approximately NOK 55 million at a subscription price of NOK 1.65 per share (the "Private Placement") and a possible subsequent offering, raising up to NOK 13,200,000, at the same subscription price as in the private placement (the "Subsequent Offering"), subject to approval by an Extraordinary General Meeting to be h ...

The board of directors of IDEX Biometrics ASA resolved on 15 May 2024 to issue 40,900 incentive subscription rights to a new individual contractor in the IDEX Biometrics group. The grant was made under the company's 2023 incentive subscription rights plan as resolved at the annual general meeting on 23 May 2023. The exercise price of the subscription rights is NOK 1.80 per share and the SRs vest by 25% per year over four years. The SRs expire on 23 May 2028. Following the grant there are 17,514,625 subscrip ...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Oslo, 15 May 2024. Reference is made to the press release from IDEX Biometrics ASA ("IDEX" or the "Company") published earlier today, 15 May 2024, regarding a contemplated private placeme ...

Wendy Palacios Good morning, everyone. This is Wendy Palacios, Vice President of FP&A and Investor Relations for IDEX Corporation. Thank you for joining us for our discussion of the IDEX first quarter 2024 financial highlights. With that, IÂ'll turn this call over to our CEO and President, Eric Ashleman. Eric Ashleman Overall, itÂ's clear that economic and geopolitical uncertainty persist as a backdrop for all companies. WeÂ've leaned into that with a conviction that the three core tenets of the IDEX differ ...

• Ag cyclically down Positive market signals continue excluding Agriculture *This presentation contains non-GAAP financial information. Reconciliations of non-GAAP measures are included either in this presentation or in our Q1 '24 earnings release. Click Here to Edit Title Q1 2024: Health & Science Technologies 7 ($ in millions) Orders -2% Organic* $351 $310 Q1'23 Q1'24 28.7%26.2% Q1'23 Q1'24 $318 $314 Q1'23 Q1'24 Sales Organic FX M&A YoY∆ Sales Growth -13% - 1% -12% Adj. EBITDA Margin* -250 bps Highlights ...